MetaCap

Aclaris Therapeutics (ACRS) vs Zevra Therapeutics (ZVRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aclaris Therapeutics (ACRS) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 37.1% versus a gain of 1.9%. Over five years, ZVRA leads with a +8.8% price change compared with -72.7% for ACRS. Aclaris Therapeutics is the larger company by market cap ($545.6 million vs $521.3 million), about 1.0 times the size, while Zevra Therapeutics is growing revenue faster (+350.9% vs -58.2%).

Zevra Therapeutics converts more of its revenue into profit, with a net margin of 78.2% versus -829.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACRS+37.05%ZVRA+1.86%
+169%+77%-14%
Nov 21, 20251 yearNov 20, 2026
ACRS-75.05%ZVRA+4.29%
+74%-14%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACRS versus ZVRA key metrics
MetricACRSZVRA
Share price$3.44$8.76
Market cap$545.63M$521.26M
1-day change-1.71%-3.42%
YTD return+14.29%-2.23%
1-year return+37.05%+1.86%
5-year return-72.74%+8.82%
P/E ratio (TTM)—7.18
Forward P/E—9.84
EPS (TTM)$-0.59$1.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.83M$106.47M
Revenue growth (YoY)-58.19%+350.91%
Net income (latest FY)$-64.92M$83.23M
Gross margin73.28%84.52%
Operating margin-975.91%-59.12%
Net margin-829.58%78.17%
52-week high$6.60$15.04
52-week low$2.46$8.01
Distance from 52-week high-47.88%-41.74%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+205.23%+162.56%
Average volume3.07M954.53K
Shares outstanding158.61M59.50M
Employees6961
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ACRS has outperformed ZVRA by 35.2 percentage points over the past year.
  • Zevra Therapeutics is more profitable, keeping 78.2 cents of every revenue dollar as net income versus -829.6 cents for Aclaris Therapeutics.
  • Zevra Therapeutics grew revenue faster in its latest fiscal year (+350.91% vs -58.19%).

About Aclaris Therapeutics

ACRS stock →

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Zevra Therapeutics

ZVRA stock →

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees

ACRS vs ZVRA FAQ

Which is bigger, Aclaris Therapeutics or Zevra Therapeutics?

Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $545.63M compared with $521.26M for Zevra Therapeutics (ZVRA).

Which stock has performed better over the past year, ACRS or ZVRA?

ACRS returned +37.05% over the past 12 months, compared with +1.86% for ZVRA (price return, excluding dividends). Past performance does not predict future results.

Are Aclaris Therapeutics and Zevra Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons